These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 19026138

  • 1. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.
    Belzunegui J, López L, Paniagua I, Intxausti JJ, Maíz O.
    Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S133-4. PubMed ID: 19026138
    [No Abstract] [Full Text] [Related]

  • 2. Worsening of osteomalacia in a patient successfully treated for neuro-Behçet's disease with infliximab.
    Madanat WY, Madanat AY.
    Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S128-9. PubMed ID: 19026133
    [No Abstract] [Full Text] [Related]

  • 3. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
    Leccese P, D'Angelo S, Angela P, Coniglio G, Olivieri I.
    Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
    [No Abstract] [Full Text] [Related]

  • 4. Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.
    Olivieri I, D' Angelo S, Padula A, Leccese P, Mennillo GA.
    Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S112. PubMed ID: 19796550
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
    Leccese P, Latanza L, D'Angelo S, Padula A, Olivieri I.
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
    [No Abstract] [Full Text] [Related]

  • 6. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy.
    Ariyachaipanich A, Berkelhammer C, Nicola H.
    Inflamm Bowel Dis; 2009 Dec; 15(12):1769-71. PubMed ID: 19177427
    [No Abstract] [Full Text] [Related]

  • 7. Adalimumab for sight-threatening uveitis in Behçet's disease.
    Mushtaq B, Saeed T, Situnayake RD, Murray PI.
    Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
    [Abstract] [Full Text] [Related]

  • 8. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N, Mizoshita T, Sugiyama T, Togawa S, Miyaki T, Suzuki T, Tanida S, Kataoka H, Sasaki M.
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [Abstract] [Full Text] [Related]

  • 9. Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature.
    Pipitone N, Olivieri I, Padula A, D'angelo S, Nigro A, Zuccoli G, Boiardi L, Salvarani C.
    Arthritis Rheum; 2008 Feb 15; 59(2):285-90. PubMed ID: 18240181
    [No Abstract] [Full Text] [Related]

  • 10. An attack of acute neuro-Behçet's disease during the course of chronic progressive neuro-Behçet's disease: report of two cases.
    Matsui T, Ishida T, Tono T, Yoshida T, Sato S, Hirohata S.
    Mod Rheumatol; 2010 Dec 15; 20(6):621-6. PubMed ID: 20617356
    [Abstract] [Full Text] [Related]

  • 11. Successful use of infliximab in a patient with neuro-Behçet's disease.
    Abalos-Medina GM, Sánchez-Cano D, Ruiz-Villaverde G, Ruiz-Villaverde R, Quirosa Flores S, Raya Alvarez E.
    Int J Rheum Dis; 2009 Sep 15; 12(3):264-6. PubMed ID: 20374357
    [Abstract] [Full Text] [Related]

  • 12. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J, Cheon JH.
    Gut Liver; 2018 Nov 15; 12(6):623-632. PubMed ID: 29788675
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy of adalimumab in Behçet's disease. Description of 6 cases].
    Calvo Catalá J, Campos Fernández C, Rueda Cid A, González-Cruz Cervellera MI, Baixauli Rubio A, Pastor Cubillo MD.
    Reumatol Clin; 2011 Nov 15; 7(4):258-61. PubMed ID: 21794828
    [Abstract] [Full Text] [Related]

  • 14. Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab.
    Sànchez-Cano D, Callejas-Rubio JL, Ortego-Centeno N, Ruiz-Villaverde R.
    Clin Exp Rheumatol; 2006 Nov 15; 24(5 Suppl 42):S128. PubMed ID: 17067448
    [No Abstract] [Full Text] [Related]

  • 15. Adalimumab: a new modality for Behçet's disease?
    van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM.
    Ann Rheum Dis; 2007 Apr 15; 66(4):565-6. PubMed ID: 17124248
    [No Abstract] [Full Text] [Related]

  • 16. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
    Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, Tanaka Y.
    Rheumatology (Oxford); 2009 Aug 15; 48(8):1012-3. PubMed ID: 19465589
    [No Abstract] [Full Text] [Related]

  • 17. Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab.
    Atzeni F, Leccese P, D'Angelo S, Sarzi-Puttini P, Olivieri I.
    Clin Exp Rheumatol; 2010 Aug 15; 28(4 Suppl 60):S94. PubMed ID: 20868581
    [No Abstract] [Full Text] [Related]

  • 18. Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature.
    Almoznino G, Ben-Chetrit E.
    Clin Exp Rheumatol; 2007 Aug 15; 25(4 Suppl 45):S99-102. PubMed ID: 17949561
    [Abstract] [Full Text] [Related]

  • 19. Successful treatment of long-standing neuro-Behçet's disease with infliximab.
    Sarwar H, McGrath H, Espinoza LR.
    J Rheumatol; 2005 Jan 15; 32(1):181-3. PubMed ID: 15630746
    [Abstract] [Full Text] [Related]

  • 20. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
    Morris DS, Gavin MP, Sturrock RD.
    Adv Exp Med Biol; 2003 Jan 15; 528():557-9. PubMed ID: 12918763
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.